Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494024 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
A Phase 1 study, sponsored by C2N Diagnostics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02494024: Completed Phase 1 study, sponsored by C2N Diagnostics.
NCT02494024 is a Phase 1 study that has completed, run by C2N Diagnostics. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02494024, a Phase 1 study, has completed, sponsored by C2N Diagnostics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).
Interventions
- DRUG Single dose placebo
- DRUG Single dose C2N-8E12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
What the finished NCT02494024 record still lists
NCT02494024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 2 interventions - of which Single dose placebo is the first listed.
NCT02494024 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02494024 about?
NCT02494024 is a clinical study titled "Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy". This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).
What is the current status of trial NCT02494024?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2015-07. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02494024?
The interventions under investigation include: Single dose placebo (DRUG), Single dose C2N-8E12 (DRUG).
Who is sponsoring clinical trial NCT02494024?
This trial is sponsored by C2N Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02494024's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia